A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

Clinical trial NCT00649584 · TERMINATED

Trial details

NCT number: NCT00649584
Sponsor: Seagen Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Disease, Hodgkin Lymphoma, Large-Cell, Anaplastic Lymphoma, Non-Hodgkin

Start date: 2008-03-01
Primary completion: 2010-02-01
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.